Safety and Efficacy of Therapies for Skin Symptoms of Psoriasis in Patients with Psoriatic Arthritis: A Systematic Review

Boehncke, Wolf‐Henning; Martínez, David Álvarez; Solomon, James A.; Gottlieb, Alice B.

doi:10.3899/jrheum.140880

Cited by 15 publications

(10 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Subsequently, we posted the principles online for further comment and to obtain agreement among GRAPPA membership. GRAPPA members updated the reviews that were previously published , reviewing subsequent literature within 6 subgroups addressing peripheral arthritis, axial disease, enthesitis, dactylitis, psoriasis, and nail disease in the setting of PsA. A central literature search was performed in collaboration with the University of Leeds Library in 2013 as detailed previously , with relevant articles provided to the groups.…”

Section: Methodsmentioning

confidence: 99%

“…In addition, a representative from each group focused on treatment safety. Each group then conducted a systematic literature review of the PsA treatment literature and excerpted and published the evidence base for treatment effect for each of the domains . We applied the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach to formulate these recommendations , which included determination of the strength of recommendation of each therapy (strong, conditional) based on the quality and breadth of evidence that the treatment can achieve desirable effects (e.g., reduction of morbidity and mortality, improvement in quality of life, reduction in burden of treatment and resource utilization), contextualized to individual patient and societal considerations .…”

mentioning

confidence: 99%

See 1 more Smart Citation

Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis

Coates

Kavanaugh

Mease

et al. 2016

Arthritis & Rheumatology

Self Cite

725

760

View full text Add to dashboard Cite

Objective To update the 2009 Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) treatment recommendations for the spectrum of manifestations affecting patients with psoriatic arthritis (PsA). Methods GRAPPA rheumatologists, dermatologists, and PsA patients drafted overarching principles for the management of PsA, based on consensus achieved at face-to-face meetings and via online surveys. We conducted literature reviews regarding treatment for the key domains of PsA (arthritis, spondylitis, enthesitis, dactylitis, skin disease, and nail disease) and convened a new group to identify pertinent comorbidities and their effect on treatment. Finally, we drafted treatment recommendations for each of the clinical manifestations and assessed the level of agreement for the overarching principles and treatment recommendations among GRAPPA members, using an online questionnaire. Results Six overarching principles had ≥80% agreement among both health care professionals (n = 135) and patient research partners (n = 10). We developed treatment recommendations and a schema incorporating these principles for arthritis, spondylitis, enthesitis, dactylitis, skin disease, nail disease, and comorbidities in the setting of PsA, using the Grading of Recommendations, Assessment, Development and Evaluation process. Agreement of >80% was reached for approval of the individual recommendations and the overall schema. Conclusion We present overarching principles and updated treatment recommendations for the key manifestations of PsA, including related comorbidities, based on a literature review and consensus of GRAPPA members (rheumatologists, dermatologists, other health care providers, and patient research partners). Further updates are anticipated as the therapeutic landscape in PsA evolves

show abstract

Section: Methodsmentioning

confidence: 99%

mentioning

confidence: 99%

Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis

Coates

Kavanaugh

Mease

et al. 2016

Arthritis & Rheumatology

Self Cite

725

760

View full text Add to dashboard Cite

show abstract

“…The role of anakinra remains uncertain. Psoriasis (for details, see Boehncke, et al 10 ). To comprehensively treat patients with both PsA and psoriasis, we must control both disease domains.…”

Section: Journal Of Rheumatologymentioning

confidence: 99%

Systematic Review of Treatments for Psoriatic Arthritis: 2014 Update for the GRAPPA

2014

View full text Add to dashboard Cite

Psoriatic arthritis (PsA) is a chronic systemic inflammatory disorder characterized by the association of arthritis and periarticular inflammation in patients with psoriasis. In addition to a heterogeneous and variable clinical course, PsA is complex and multifaceted and may include prominent involvement in the peripheral and axial diarthrodial joints, the skin and nails, and in periarticular structures such as entheses. Simultaneous inflammation in the skin and musculoskeletal structures in a single patient, a relatively common scenario, often leads to marked decrease in function and quality of life. Thus, it is essential for the clinician to document the extent of disease involvement and craft a therapeutic plan that addresses the different domains of disease. In an effort to update previous treatment recommendations developed by the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), several evidence-based, systemic reviews of therapies for PsA were completed, analyzed, and circulated for consensus.

show abstract

“…It is also important to note PSAI and many other instruments are not developed on a metric scale, which introduce systematic bias to the studies that included patients with mild skin disease [Leung et al 2014b]. A systematic review by GRAPPA, which included 25 studies, revealed both DMARDs (MTX, LEF, cyclosporine A) and biologics (mainly anti-TNFs) have some efficacy as therapy for skin PsO [Boehncke et al 2014]. Looking forward, it will be important to develop appropriate outcome measures on metric scale to be used in clinical trials.…”

Section: Treatment Of Psamentioning

confidence: 99%

Making the next steps in psoriatic arthritis management: current status and future directions

Sritheran

Leung

2015

Therapeutic Advances in Musculoskeletal

View full text Add to dashboard Cite

Psoriatic arthritis (PsA) is a chronic inflammatory condition with articular and extraarticular manifestations: peripheral arthritis, axial disease, enthesitis, dactylitis, and skin and nail disease. It is associated with cardiovascular comorbidities. It is now recognized as a new entity, different from rheumatoid arthritis and other spondyloarthritis in terms of clinical manifestations, pathogenesis, and response to therapies. Anti-tumor necrosis factors (antiTNFs) have demonstrated clinical efficacies exceeding that of conventional disease modifying antirheumatic drugs (DMARDs). The current treatment paradigms recommend early diagnosis and treatment, and a strategic and target orientated approach, aiming at a low disease activity status. New understanding in the immunopathogenesis of PsA has led to new treatment targets. This review addresses the evidence of current treatment for each of the domains as an aid to the clinician managing these patients in the clinic. Some new therapeutic targets are presented. We highlight the importance of development and validation in outcome measures, including that of composite scores that capture various disease domains that will facilitate future clinical trials to inform the best treatment.

show abstract

Safety and Efficacy of Therapies for Skin Symptoms of Psoriasis in Patients with Psoriatic Arthritis: A Systematic Review

Cited by 15 publications

References 28 publications

Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis

Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis

Systematic Review of Treatments for Psoriatic Arthritis: 2014 Update for the GRAPPA

Making the next steps in psoriatic arthritis management: current status and future directions

Contact Info

Product

Resources

About